Skip to search formSkip to main contentSkip to account menu

BTK Inhibitor GDC-0853

Known as: Bruton Tyrosine Kinase Inhibitor GDC-0853, GDC-0853 
An orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, GDC-0853 inhibits the… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL
[This corrects the article DOI: 10.18632/oncotarget.24310.]. 
Review
2018
Review
2018
New biologics in the treatment of urticaria
Purpose of review Symptomatic management of chronic spontaneous urticaria (CSU) basically depends on second-generation H1… 
2017
2017
Bruton’s Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats
Bruton’s tyrosine kinase (BTK) is a member of the Tec family of cytoplasmic tyrosine kinases involved in B-cell and myeloid cell… 
2016
2016
GDC-0853 inhibits both wild type and C481S BTK variants while preserving NK cell mediated ADCC
Professional Biological Sciences: 3rd Place (The Ohio State University Edward F. Hayes Graduate Research Forum) 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)